Skip to main content

Table 3 Acute hematologic toxicity

From: Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial

Toxicity

PBMS group n (%)

Control group n (%)

p

HT2+

41 (50.0)

57 (69.5)

0.02a

Leukopenia

 Grade 0

13 (15.9)

8 (9.8)

< 0.01a

 Grade 1

32 (39.0)

22 (26.8)

 Grade 2

35 (42.7)

37 (45.1)

 Grade 3

2 (2.4)

15 (18.3)

 Grade 4

0

0

Neutropenia

 Grade 0

51 (62.2)

35 (42.7)

<0.01a

 Grade 1

20 (24.4)

11 (13.4)

 Grade 2

9 (11.0)

30 (36.6)

 Grade 3

2 (2.4)

5 (6.1)

 Grade 4

0

1 (1.2)

Anemia

 Grade 0

68 (82.9)

52 (63.4)

0.02a

 Grade 1

10 (12.2)

19 (23.2)

 Grade 2

4 (4.9)

11 (13.4)

 Grade 3

0

0

 Grade 4

0

0

Thrombocytopenia

 Grade 0

81 (98.8)

68 (82.9)

< 0.01a

 Grade 1

1 (1.2)

10 (12.2)

 Grade 2

0

2 (2.4)

 Grade 3

0

1 (1.2)

 Grade 4

0

1 (1.2)

GT2+

29 (35.4)

31 (37.8)

0.75

 Grade 0

14 (17.1)

17 (20.7)

0.68

 Grade 1

39 (47.6)

34 (41.5)

 Grade 2

29 (35.4)

31 (37.8)

 Grade 3

0

0

 Grade 4

0

0

  1. Abbreviation: HT2+ hematologic toxicity of grade ≥ 2, GT2+ gastrointestinal toxicity of grade ≥ 2
  2. aStatistically significant